Wednesday, July 8, 2026

pharma · Advanced solid tumors · Advanced Solid Tumors · TTRX

Turn Therapeutics

Turn Therapeutics (Nasdaq: is a pharma organization headquartered in Westlake Village, USA. It trades on NYSE under ticker TTRX. Primary therapeutic focus areas include Advanced solid tumors, Advanced Solid Tumors, Covid

Westlake Village, USA HQ
2015 Founded
11 Employees
Public company Type
TTRX · NYSE Ticker
Company details
Status
Public
HQ
Westlake Village, USA
Founded
2015
Employees
11
Programs
6
Drugs
3
Patents
40
Clinical program

GX-03

Phase 2 · small molecule · Covid19

GX-03 for Covid19 is a Phase 2 program (small_molecule) at Turn Therapeutics with 1 ClinicalTrials.gov record(s).

← All Turn Therapeutics projects Phase 2 small molecule completed

Internal code GX-03 for COVID-19

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Turn Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Covid19
Status
completed
Trials
1

Clinical trials